Key result
Higher serum TMAO levels were significantly associated with peripheral arterial stiffness in patients with advanced non-dialysis CKD (OR 1.016; 95% CI 1.002-1.029; p=0.021).
Why the study?
TMAO is a gut-derived uremic toxin involved in CVD, and the study aimed to determine its correlation with peripheral arterial stiffness in patients with advanced CKD.
Are higher serum TMAO levels associated with peripheral arterial stiffness in patients with advanced non-dialysis CKD?
Cross-Sectional (n=157)
Are higher serum TMAO levels associated with peripheral arterial stiffness in patients with advanced non-dialysis CKD?
Odds Ratio: 1.016 (95% CI 1.002–1.029)
p-value: p=0.021
Higher serum TMAO levels are independently associated with increased peripheral arterial stiffness in patients with advanced non-dialysis CKD, suggesting a potential mechanism for cardiovascular risk in this population.
Supports TMAO-stiffness link in advanced non-dialysis CKD; hypothesis-generating, prospective studies needed before clinical adoption.
Trimethylamine N-oxide (TMAO) is a gut-derived uremic toxin involved in cardiovascular diseases (CVD). Peripheral arterial stiffness (PAS), measured by the brachial-ankle pulse wave velocity (baPWV) is a valuable indicator of the existence of CVD alongside other diseases. The study recruited 157 patients with chronic kidney disease (CKD) stages 3 to 5, and aimed to determine the correlation between serum TMAO and PAS, defined as a baPWV of >18.0 m/s. Patients with CKD who were diagnosed with PAS (68 patients, 43.3%) were older, had a higher percentage of hypertension or diabetes mellitus, higher systolic blood pressure, and higher fasting glucose, C-reactive protein, and TMAO levels. Furthermore, besides old age and SBP, patients with CKD who had higher serum TMAO were more likely to have PAS, with an odds ratio of 1.016 (95% confidence interval = 1.002−1.029, p = 0.021) by multivariate logistic regression analysis. Correlation analysis demonstrated that serum TMAO was positively correlated with C-reactive protein level and either left or right baPWV. Thus, we supposed that serum TMAO levels were associated with PAS in patients with advanced non-dialysis CKD.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2022) conducted a cross-sectional in Chronic kidney disease (CKD) stages 3 to 5 (n=157). Serum Trimethylamine N-Oxide (TMAO) level vs. Lower serum TMAO levels was evaluated on Peripheral arterial stiffness (PAS), defined as a baPWV of >18.0 m/s (OR 1.016, 95% CI 1.002-1.029, p=0.021). Higher serum TMAO levels were significantly associated with peripheral arterial stiffness in patients with advanced non-dialysis CKD (OR 1.016; 95% CI 1.002-1.029; p=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: